Detail akcie Genprex Rg online

Business Summary: Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Genprex Inc revenues was not reported. Net loss decreased 26% to $12.4M. Lower net loss reflects General and administrative decrease of 48% to $4.8M (expense), Research and development decrease of 6% to $7.2M (expense), Depreciation decrease from $6K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$396.32 to -$26.45.